Skip to main content

Celularity, Inc. (CELU)

NASDAQ: CELU · IEX Real-Time Price · USD
6.92 -0.10 (-1.36%)
Oct 22, 2021 3:10 PM EDT - Market open
Market Cap867.62M
Revenue (ttm)20.14M
Net Income (ttm)-355.13M
Shares Out23.99M
EPS (ttm)-7.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume48,953
Open7.07
Previous Close7.01
Day's Range6.81 - 7.15
52-Week Range6.00 - 13.40
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About CELU

Celularity Inc., a clinical stage biotechnology company, develops placental-derived allogeneic cell therapies. The company offers genetically modified and unmodified NK cells; engineered T cells, including CAR-T cells; and mesenchymal-like adherent stromal cells targeting indications across cancer, immunologic, infectious, and degenerative diseases. It also offers cell therapy candidates in pre-clinical and clinical development, as well as placental-derived products for surgical use. The company was founded in 2016 and is based in Florham Park,...

IndustryBiotechnology
Founded2016
Employees162
Stock ExchangeNASDAQ
Ticker SymbolCELU
Full Company Profile

Financial Performance

In 2020, Celularity's revenue was $14.28 million, a decrease of -32.48% compared to the previous year's $21.15 million. Losses were -$208.23 million, -1.72% less than in 2019.

Financial Statements

News

Celularity Appoints Andrew L. Pecora, M.D.

Renowned clinician, scientist and proven executive leader in biotechnology and healthcare with more than 25 years' experience developing life-changing cellular medicines Renowned clinician, scientist an...

1 month ago - GlobeNewsWire

Celularity Reports Second Quarter 2021 Financial Results

FLORHAM PARK, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”) (Nasdaq:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies...

2 months ago - GlobeNewsWire

Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CA...

SYDNEY, Australia and FLORHAM PARK, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company and Celularity Inc. (“Celularity”) (Nasdaq: CELU)...

2 months ago - GlobeNewsWire

Why GX Acquisition Stock Soared Today

The SPAC closed its merger with clinical-stage biotech Celularity.

3 months ago - The Motley Fool

GXGX Merger: The SPAC News That Has GXGX Stock Soaring

GXGX's merger announcement is causing the stock to soar this afternoon. The SPAC is merging with biotech play Celularity.

Other symbols:PLTR
3 months ago - InvestorPlace

Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update

Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol “CELU” on July 19, 2021

3 months ago - GlobeNewsWire

GX Acquisition Corp. Announces Shareholder Approval of Extension Proposal

NEW YORK, May 14, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, announced today that its stockholders have voted to approve an a...

5 months ago - PRNewsWire

GX Acquisition Corp. Announces Additional Contributions to Trust Account

NEW YORK, May 10, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, today reaffirmed its intention to support the proposal to amend ...

5 months ago - PRNewsWire

GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination

NEW YORK, April 16, 2021 /PRNewswire/ -- On April 14, 2021, GX Acquisition Corp. ("GX") (NASDAQ: "GXGX"), provided information regarding a proposal to amend GX's amended and restated certificate of inco...

6 months ago - PRNewsWire

7 Upcoming SPAC Mergers to Avoid

The stock market has suddenly broken to the downside over the past two weeks. That makes these SPACs particularly risky bets as the momentum fades.

Other symbols:AGBA
7 months ago - InvestorPlace